Eccogene and AstraZeneca to Present New Clinical Data on Elecoglipron at ADA 2026 Scientific Sessions
Clinical-stage biopharmaceutical company Eccogene has announced that new clinical findings for elecoglipron (AZD5004/ECC5004), its investigational oral GLP-1 receptor agonist, will be featured at the 2026 Scientific Sessions of the American Diabetes Association (ADA). The presentations will highlight the latest progress in the development of the oral therapy for obesity, overweight, and type 2 diabetes, reflecting growing momentum behind one of the industry’s most closely watched cardiometabolic treatment programs.
The ADA Scientific Sessions, one of the largest and most influential global conferences focused on diabetes research and care, will be held from June 5 to June 8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Researchers, clinicians, healthcare professionals, and industry leaders from around the world are expected to attend the event to review emerging scientific advances and clinical innovations.
At the conference, Eccogene will present results from a Phase 1b clinical study conducted in China that evaluated elecoglipron in adults living with obesity or overweight, both with and without type 2 diabetes. The study findings have been selected for a late-breaking poster presentation, underscoring the significance of the data and its potential contribution to the rapidly evolving field of metabolic disease treatment.
Elecoglipron is an investigational oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 therapies have become a cornerstone of treatment for obesity and type 2 diabetes due to their ability to support weight loss, improve glycemic control, and potentially provide broader cardiometabolic benefits. While many currently available GLP-1 therapies require injection, elecoglipron is being developed as an oral treatment option, which could offer patients greater convenience and accessibility.
According to Eccogene, the ADA presentations mark an important milestone in the advancement of the elecoglipron development program. Company leadership emphasized that the upcoming presentations reflect both scientific progress and the strength of its global collaboration with AstraZeneca.
Jingye Zhou, Ph.D., Chief Executive Officer of Eccogene, described the ADA presentations as a significant moment for the company and its research efforts. He noted that showcasing the latest clinical findings at one of the world’s premier diabetes conferences demonstrates the rapid advancement of elecoglipron and highlights the growing interest in oral GLP-1 therapies as potential treatment options for patients with obesity and type 2 diabetes.
The late-breaking poster presentation from Eccogene will focus on the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of elecoglipron in Chinese adults affected by obesity or overweight conditions. Researchers evaluated the drug’s performance among participants both with and without type 2 diabetes, providing valuable insights into its clinical profile across diverse patient populations.
The presentation is titled “Safety, Tolerability, PK, and PD of Elecoglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Chinese Adults Living with Obesity or Overweight with or without Type 2 Diabetes.”
The poster will be presented by Jai Patel, MBBS, MRCP(UK), Chief Medical Officer of Eccogene Inc. The session is scheduled for Sunday, June 7, 2026, from 12:30 p.m. to 1:30 p.m. Central Time in the Poster Hall, located in Halls D and E of the convention center. The poster has been assigned number 2844-LB.
Beyond Eccogene’s own presentation, additional data from elecoglipron will be showcased by AstraZeneca, which obtained exclusive global rights to develop and commercialize the therapy outside Greater China through a licensing agreement with Eccogene. AstraZeneca plans to present findings from two global Phase 2b clinical studies during a dedicated symposium at the ADA meeting.
The symposium, titled “AZD5004, A Novel Oral Small Molecule GLP-1 Receptor Agonist: Overweight/Obesity (VISTA) and Type 2 Diabetes (SOLSTICE) Phase 2 Trial Results,” is scheduled for Monday, June 8, 2026, from 3:15 p.m. to 4:15 p.m. Central Time in Great Hall A.
The first presentation within the symposium will focus on the VISTA study, a Phase 2b randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of AZD5004 in individuals living with obesity or overweight conditions accompanied by related comorbidities. Researchers will discuss the impact of the therapy on body weight and other clinically relevant metabolic measures while also examining its safety profile.
The VISTA presentation will take place from 3:15 p.m. to 3:35 p.m. Central Time.
The second presentation will highlight results from the SOLSTICE study, another Phase 2b clinical trial that investigated AZD5004 in adults diagnosed with type 2 diabetes mellitus. The study utilized a randomized, double-blind, placebo-controlled design and also included an open-label active comparator arm. Investigators evaluated the drug’s effectiveness in improving glycemic control while assessing safety and tolerability outcomes across the study population.
The SOLSTICE presentation is scheduled from 3:35 p.m. to 3:55 p.m. Central Time.
Following the two scientific presentations, an independent expert commentary session will be conducted from 3:55 p.m. to 4:15 p.m. Central Time. The discussion is expected to provide additional context regarding the significance of the findings and their potential implications for future treatment strategies in obesity and type 2 diabetes.
The coordinated presentations from both Eccogene and AstraZeneca demonstrate the breadth of ongoing research supporting elecoglipron’s development. Together, the studies span early-stage clinical evaluation through mid-stage global trials, offering a comprehensive view of the therapy’s potential role in addressing major unmet needs within the cardiometabolic disease landscape.
The growing prevalence of obesity and type 2 diabetes continues to create substantial challenges for healthcare systems worldwide. As demand increases for effective and convenient treatment options, oral GLP-1 receptor agonists have emerged as an area of intense scientific and commercial interest. Researchers believe that oral formulations could help expand patient access by providing an alternative to injectable therapies while maintaining meaningful clinical benefits.
For Eccogene, the ADA presentations represent an opportunity to showcase the company’s innovation capabilities and its progress in developing next-generation oral therapeutics for chronic cardiometabolic and inflammatory diseases. The company has focused on creating small-molecule medicines that combine efficacy with patient-friendly administration, aiming to improve long-term treatment adherence and outcomes.
The collaboration between Eccogene and AstraZeneca has further accelerated the global development of elecoglipron. By leveraging AstraZeneca’s extensive clinical development expertise and global commercial infrastructure, the partners hope to advance the therapy efficiently through later-stage studies and regulatory pathways.
Attendees of the ADA Scientific Sessions will gain access to new clinical evidence regarding elecoglipron’s safety, tolerability, pharmacological characteristics, and therapeutic potential. The data are expected to contribute to ongoing discussions about the future of oral GLP-1 receptor agonists and their role in managing obesity and type 2 diabetes.
In accordance with ADA policies, conference abstracts are expected to be made available through the meeting platform. Following the conference, Eccogene also plans to publish its late-breaking poster presentation on the company’s website, enabling broader access to the research findings for healthcare professionals, researchers, investors, and other stakeholders interested in the development of innovative metabolic disease therapies.
As the ADA 2026 meeting approaches, the presentation of multiple clinical datasets from Eccogene and AstraZeneca highlights the increasing momentum surrounding elecoglipron and reinforces its position as a promising investigational oral therapy in the evolving GLP-1 treatment landscape.
About Elecoglipron
Elecoglipron is an investigational oral, small-molecule GLP-1 receptor agonist discovered by Eccogene. It is designed to offer a convenient once-daily dosing regimen with no food- or water-related restrictions, which may help support patient adherence and broaden access. In November 2023, Eccogene entered into a global licensing agreement with AstraZeneca for elecoglipron, while retaining co-development and co-commercialization rights in Greater China.
